News blog

FDA chemist charged with insider trading

Few are better placed to beat the market – illegally – than employees intimately involved with new drug marketing approvals at the US Food and Drug Administration (FDA). The temptation was apparently too much for Cheng Yi Liang, a 57-year-old chemist in FDA’s Center for Drug Evaluation and Research (CDER), the agency power center that approves new drugs (building at right). 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE